-
Government & Regulation
Thailand Insurance Industry – Governance, Risk and Compliance
Thailand Insurance Industry Regulation Overview Office of Insurance Commission (OIC) regulates the Thailand insurance industry along with other regulators and supervisors, including the International Association of Insurance Supervisors (IAIS), Thai General Insurance Association (TGIA), and the Thai Life Assurance Association (TLAA). The Thailand insurance industry governance regulation research report provides a detailed analysis of the regulations for several insurance types including life, property, motor, and liability. The report also gives insights into recent and upcoming changes in non-admitted insurance regulations,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axelopran in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axelopran in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axelopran in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axelopran in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axelopran in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axelopran in Pancreatic Cancer Drug Details: Axelopran is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naldemedine Tosylate in Pancreatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naldemedine Tosylate in Pancreatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naldemedine Tosylate in PancreatitisDrug Details:Naldemedine tosylate (S-297995, Symproic) is an opioid antagonist. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axelopran in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axelopran in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axelopran in Recurrent Head And...
-
Product Insights
Net Present Value Model: Relistor
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Relistor Drug Details Methylnaltrexone bromide (Relistor)...
-
Product Insights
Net Present Value Model: Symproic
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Symproic Drug Details Naldemedine tosylate (S-297995,...
-
Product Insights
Net Present Value Model: Movantik
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Movantik Drug Details Naloxegol oxalate (Movantik, Moventig,...
-
Product Insights
Net Present Value Model: Moventig
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Moventig Drug Details Naloxegol oxalate (Movantik, Moventig,...
-
Product Insights
Net Present Value Model: Linzess
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Linzess Drug Details Linaclotide (Linzess, Constella,...